

Hepatitis B Virus Healthy Volunteers

**A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants**

**Trial Status**  
Completed

**Trial Runs In**  
8 Countries

**Trial Identifier**  
NCT02952924 YP39364

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study is a multicenter, three-part study. Parts 1 and 2 are randomized, investigator- and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7049389 following oral administration in healthy volunteers and chronic HBV infected participants. Part 3 is a non-randomized, non-controlled, open-label part to assess the efficacy and safety of RO7049389 when administered in combination with standard-of-care therapies for up to 48 weeks in nucleos(t)ide (NUC)-suppressed and treatment-naive chronic hepatitis B (CHB) participants.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT02952924 YP39364**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years & <= 60 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---